Total Payments
$188,040
2024 Payments
$51,003
Companies
27
Transactions
151
Medicare Patients
12,056
Medicare Billing
$3.5M
Payment Breakdown by Category
Consulting$121,434 (64.6%)
Research$32,262 (17.2%)
Travel$21,678 (11.5%)
Other$6,562 (3.5%)
Food & Beverage$5,979 (3.2%)
Education$104.90 (0.1%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $121,434 | 30 | 64.6% |
| Unspecified | $32,262 | 11 | 17.2% |
| Travel and Lodging | $21,678 | 17 | 11.5% |
| Food and Beverage | $5,979 | 85 | 3.2% |
| Honoraria | $3,563 | 3 | 1.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000 | 1 | 1.6% |
| Education | $104.90 | 3 | 0.1% |
| Gift | $19.40 | 1 | 0.0% |
Payments by Type
General
$155,778
140 transactions
Research
$32,262
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $62,671 | 13 | $0 (2024) |
| Astellas Pharma Global Development | $51,750 | 12 | $0 (2024) |
| Chugai Pharmaceutical Co., Ltd. | $18,767 | 3 | $0 (2023) |
| Allergan, Inc. | $15,046 | 24 | $0 (2021) |
| Dutch Ophthalmic, USA | $11,803 | 7 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $9,714 | 14 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $4,515 | 4 | $0 (2023) |
| Alimera Sciences, Inc. | $3,954 | 7 | $0 (2024) |
| F. Hoffmann-La Roche AG | $2,128 | 2 | $0 (2024) |
| Genentech USA, Inc. | $2,050 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $51,003 | 45 | Astellas Pharma Global Development ($29,150) |
| 2023 | $104,582 | 29 | Regeneron Pharmaceuticals, Inc. ($50,673) |
| 2022 | $2,575 | 8 | EyePoint Pharmaceuticals US, Inc. ($2,065) |
| 2021 | $4,224 | 9 | Genentech USA, Inc. ($1,980) |
| 2020 | $2,211 | 4 | EyePoint Pharmaceuticals US, Inc. ($1,500) |
| 2019 | $4,694 | 18 | EyePoint Pharmaceuticals US, Inc. ($2,393) |
| 2018 | $11,265 | 20 | Allergan Inc. ($9,692) |
| 2017 | $7,486 | 18 | Allergan Inc. ($3,641) |
All Payment Transactions
151 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Alimera Sciences, Inc. | YUTIQ (Drug) | Honoraria | Cash or cash equivalent | $1,562.50 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 12/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Consulting Fee | Cash or cash equivalent | $925.00 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 12/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | Dutch Ophthalmic, USA | EVA, combined machine (Device), TISSUEBLUE | Travel and Lodging | In-kind items and services | $839.68 | General |
| Category: Ophthalmology | ||||||
| 11/15/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | In-kind items and services | $448.80 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: OPHTHALMOLOGY | ||||||
| 10/30/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| Category: Ophthalmology | ||||||
| 10/19/2024 | Carl Zeiss Meditec USA, Inc. | — | Food and Beverage | In-kind items and services | $168.89 | General |
| 10/18/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $17.53 | General |
| 10/08/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug) | Education | In-kind items and services | $2.95 | General |
| Category: Ophthalmology | ||||||
| 10/02/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/19/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 09/19/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $28.17 | General |
| 08/28/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 08/19/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug) | Education | In-kind items and services | $2.95 | General |
| Category: Ophthalmology | ||||||
| 08/14/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: Ophthalmology | ||||||
| 07/31/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| Category: Ophthalmology | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | In-kind items and services | $4,410.30 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: OPHTHALMOLOGY | ||||||
| 05/14/2024 | Carl Zeiss Meditec USA, Inc. | — | Food and Beverage | In-kind items and services | $72.38 | General |
| 04/18/2024 | Carl Zeiss Meditec, Inc. | CIRRUS HD-OCT (Device), Humphrey HFA, IOLMaster 700 | Consulting Fee | Cash or cash equivalent | $810.00 | General |
| Category: Optical Tomography | ||||||
| 03/12/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $118.01 | General |
| Category: Ophthalmology | ||||||
| 03/12/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $107.75 | General |
| Category: Ophthalmology | ||||||
| 02/26/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $448.80 | Research |
| Study: EYLEA CLINICAL DEVELOPMENT PROGRAM • Category: OPHTHALMOLOGY | ||||||
| 02/23/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| Category: Ophthalmology | ||||||
| 02/23/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration | Astellas Pharma Global Development | $22,600 | 5 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $4,859 | 2 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $4,803 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 2,867 | 20,451 | $3.6M | $1.1M |
| 2022 | 16 | 3,277 | 7,936 | $3.2M | $972,579 |
| 2021 | 18 | 3,147 | 6,979 | $3.0M | $898,822 |
| 2020 | 14 | 2,765 | 5,371 | $2.2M | $609,719 |
Total Patients
12,056
Total Services
40,737
Medicare Billing
$3.5M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 43 | 14,700 | $1.1M | $427,910 | 40.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 57 | 436 | $628,712 | $301,979 | 48.0% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 891 | 1,601 | $465,891 | $135,907 | 29.2% |
| 92134 | Imaging of retina | Office | 2023 | 939 | 1,910 | $328,520 | $53,224 | 16.2% |
| 67028 | Injection of drug into eye | Office | 2023 | 152 | 535 | $538,856 | $47,363 | 8.8% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 17 | 231 | $128,205 | $36,614 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 103 | 103 | $40,170 | $11,252 | 28.0% |
| 67028 | Injection of drug into eye | Facility | 2023 | 42 | 139 | $144,714 | $10,393 | 7.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 54 | 148 | $22,200 | $8,232 | 37.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 61 | 83 | $40,504 | $7,690 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 115 | 121 | $30,855 | $7,466 | 24.2% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 12 | 12 | $62,196 | $7,134 | 11.5% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 271 | 284 | $28,116 | $4,497 | 16.0% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 12 | 13 | $20,150 | $3,237 | 16.1% |
| 92250 | Photography of the retina | Office | 2023 | 59 | 78 | $14,742 | $1,951 | 13.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 27 | 43 | $15,953 | $1,476 | 9.3% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 12 | 14 | $4,606 | $551.85 | 12.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 85 | 796 | $1.1M | $573,074 | 49.9% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 788 | 1,196 | $348,036 | $98,520 | 28.3% |
| 92134 | Imaging of retina | Office | 2022 | 1,004 | 2,005 | $344,860 | $56,795 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 291 | 592 | $150,960 | $52,623 | 34.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 164 | 578 | $562,433 | $51,230 | 9.1% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2022 | 25 | 315 | $174,825 | $49,779 | 28.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 19 | 1,272 | $141,669 | $37,958 | 26.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 494 | 561 | $55,539 | $9,737 | 17.5% |
About Dr. Dilraj Grewal, MD
Dr. Dilraj Grewal, MD is a Ophthalmology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2010. The National Provider Identifier (NPI) number assigned to this provider is 1437460656.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dilraj Grewal, MD has received a total of $188,040 in payments from pharmaceutical and medical device companies, with $51,003 received in 2024. These payments were reported across 151 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($121,434).
As a Medicare-enrolled provider, Grewal has provided services to 12,056 Medicare beneficiaries, totaling 40,737 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Chicago, IL
- Active Since 06/23/2010
- Last Updated 01/10/2014
- Taxonomy Code 207W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1437460656
Products in Payments
- EYLEA (Biological) $54,836
- Izervay (Drug) $51,750
- EVA, combined machine (Device) $12,534
- OZURDEX (Drug) $11,448
- YUTIQ (Drug) $8,689
- EYLEA HD (Biological) $4,881
- KEVZARA SARILUMAB INJECTION (Biological) $3,066
- Lucentis (Biological) $2,174
- DEXYCU (Drug) $1,603
- Iluvien (Drug) $1,218
- CIRRUS HD-OCT (Device) $993.34
- EYP-1901 (Drug) $925.00
- EVA Ophthalmic Surgical System (Device) $500.00
- XIPERE (Drug) $348.70
- Constellation (Device) $340.13
- NGENUITY (Device) $210.85
- Spectralis (Device) $204.63
- AcrySof IQ PanOptix (Device) $187.00
- ARTEVO 800 (Device) $141.73
- EYP-1901 $129.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Chicago
Seenu Hariprasad
Ophthalmology — Payments: $2.4M
Ophthalmology $2.4M
Dr. Yannek Leiderman, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $512,224
Ophthalmology $512,224
Jennifer Lim, M.d, M.D
Ophthalmology — Payments: $253,265
Ophthalmology $253,265
Asim Farooq
Ophthalmology — Payments: $210,059
Ophthalmology $210,059
Surendra Basti, Md, MD
Ophthalmology — Payments: $163,230
Ophthalmology $163,230
Ahmad Aref, M.d, M.D
Ophthalmology — Payments: $153,344
Ophthalmology $153,344